AURANOFIN - NEW ORAL GOLD COMPOUND FOR TREATMENT OF RHEUMATOID-ARTHRITIS
AURANOFIN - NEW ORAL GOLD COMPOUND FOR TREATMENT OF RHEUMATOID-ARTHRITIS
复制标题
DOI：
10.1136/ard.35.3.251
复制
发表时间：
1976-01-01
影响因子：
27.4
通讯作者：
MISHER, A
中科院分区：
文献类型：
--
作者：
FINKELSTEIN, AE;WALZ, DT;MISHER, A
用SK & F D-39162（金诺芬）治疗了8例类风湿性关节炎患者，这是一种新的口服金化合物，可有效抑制大鼠关节炎。临床和体液参数进行了研究，在3个月期间的药物管理，随后3个月期间的安慰剂。该药物被吸收，耐受性良好，其作用表现为治疗第三周平均IgG血液水平下降，口服金摄入5周后临床改善。与IgG变化一起，观察到白蛋白比率增加，以及α 2-球蛋白和类风湿因子滴度降低。最初在8例患者中发现的60个肿胀关节总数中，仅17个在第12周肿胀，9个在第15周肿胀。尽管接受治疗的患者数量太少，无法得出明确的结论，但在另一个3个月期间对相同患者进行的安慰剂临床和实验室变化的随访研究显示，在停药后疾病活动爆发之前，IgG血清水平迅速恢复。这证实了新的口服金化合物在因果关系中的直接作用。
Eight patients with rheumatoid arthritis were treated with SK & F D-39162 (auranofin), a new oral gold compound which was effective in suppressing adjuvant-induced arthritis in rats. Clinical and humoral parameters were studied during a 3-month period of drug administration followed by a 3-month period under placebo. The drug was absorbed, well tolerated, and its action was manifested by a drop in the mean IgG blood levels in the third week of treatment accompanied by clinical improvement after 5 weeks of oral gold intake. Together with IgG changes, an increase of the albumin ratio was observed, as well as a decrease of alpha2-globulin and rheumatoid factor titres. From a total number of 60 swollen joints found initially in the 8 patients only 17 were swollen at week 12 and 9 at week 15. Although the number of patients treated was too small to allow definite conclusions, a follow-up study under placebo of clinical and laboratory changes in the same patients during another 3-month period showed that IgG serum levels rapidly reverted preceding a flare up of disease activity after withdrawal of the drug. This confirmed a direct role in cause-effect relation played by the new oral gold compound.